These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1133 related articles for article (PubMed ID: 31730903)

  • 1. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy.
    Lei X; Lei Y; Li JK; Du WX; Li RG; Yang J; Li J; Li F; Tan HB
    Cancer Lett; 2020 Feb; 470():126-133. PubMed ID: 31730903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Killing the "BAD": Challenges for immunotherapy in pancreatic cancer.
    Li TJ; Wang WQ; Yu XJ; Liu L
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188384. PubMed ID: 32531324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preface: More than two decades of modern tumor immunology.
    Galluzzi L; Rudqvist NP
    Methods Enzymol; 2019; 629():xxi-xl. PubMed ID: 31727259
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.
    Grosser R; Cherkassky L; Chintala N; Adusumilli PS
    Cancer Cell; 2019 Nov; 36(5):471-482. PubMed ID: 31715131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized Immuno-Oncology.
    Jain KK
    Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
    Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L
    J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for hepatocellular carcinoma.
    Zongyi Y; Xiaowu L
    Cancer Lett; 2020 Feb; 470():8-17. PubMed ID: 31811905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
    Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cancer immunotherapy].
    Kjeldsen JW; Donia M; Svane IM
    Ugeskr Laeger; 2018 May; 180(21):. PubMed ID: 29804567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy.
    Bazhin AV; Amedei A; Karakhanova S
    Front Immunol; 2018; 9():2878. PubMed ID: 30568661
    [No Abstract]   [Full Text] [Related]  

  • 11. The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.
    Liberini V; Laudicella R; Capozza M; Huellner MW; Burger IA; Baldari S; Terreno E; Deandreis D
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33920423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).
    Ascierto PA; Brugarolas J; Buonaguro L; Butterfield LH; Carbone D; Daniele B; Ferris R; Fox BA; Galon J; Gridelli C; Kaufman HL; Klebanoff CA; Melero I; Nathan P; Paulos CM; Ruella M; Sullivan R; Zarour H; Puzanov I
    J Immunother Cancer; 2018 Jul; 6(1):69. PubMed ID: 29996914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
    Mooradian MJ; Sullivan RJ
    Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.
    Yoon DH; Osborn MJ; Tolar J; Kim CJ
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the tumor microenvironment and T cell metabolism for effective cancer immunotherapy.
    Hope HC; Salmond RJ
    Eur J Immunol; 2019 Aug; 49(8):1147-1152. PubMed ID: 31270810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treg-mediated acquired resistance to immune checkpoint inhibitors.
    Saleh R; Elkord E
    Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy.
    Yang P; Meng M; Zhou Q
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188558. PubMed ID: 33933558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
    Jiang Y; Chen M; Nie H; Yuan Y
    Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.